GuiZhou SanLi Pharmaceutical Co.,Ltd

603439

CNE1000040B4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
16.3 ^CNY	+2.97%		+2.19%	-13.67%

04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Guizhou Sanli Pharmaceutical Co.,Ltd(XSSC:603439) added to S&P Global BMI Index

September 18, 2023 at 12:00 am

Latest news about GuiZhou SanLi Pharmaceutical Co.,Ltd

Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 4, 2023.	12-08	CI
Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on November 4, 2023, has closed with 1,550,900 shares, representing 0.38% for CNY 29.99 million.	12-06	CI
Guizhou Sanli Pharmaceutical Co.,Ltd announces an Equity Buyback for CNY 40 million worth of its shares.	11-03	CI
Guizhou Sanli Pharmaceutical Co.,Ltd authorizes a Buyback Plan.	11-02	CI
Guizhou Sanli Pharmaceutical Co.,Ltd completed the acquisition of 50.26% stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian.	23-10-29	CI
Shanghai Guosheng Haitong Private Enterprise High-Quality Development Private Investment Fund and Shanghai Guosheng Capital Management Co., Ltd. completed the acquisition of 5.0017% stake in Guizhou Sanli Pharmaceutical Co.,Ltd(SHSE:603439) from Wang Huiying.	23-10-29	CI
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Guizhou Sanli Pharmaceutical Co.,Ltd agreed to acquire a stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian	23-09-22	CI
Guizhou Sanli Pharma Plans Acquisition for CNY 499.6 Million	23-09-22	CI
Guizhou Sanli Pharmaceutical Co.,Ltd(XSSC:603439) added to S&P Global BMI Index	23-09-18	CI
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Shanghai Guosheng Haitong Private Enterprise High-Quality Development Private Investment Fund and Shanghai Guosheng Capital Management Co., Ltd. entered into 5.0017% stake in Guizhou Sanli Pharmaceutical Co.,Ltd from Wang Huiying for CNY 322.875 million.	23-07-30	CI
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Certain A Shares of GuiZhou SanLi Pharmaceutical Co.,LTD. are subject to a Lock-Up Agreement Ending on 28-APR-2023.	23-04-27	CI
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Guizhou Sanli Pharma Sees Up to 42.5% Jump in 2022 Profit	23-01-09	MT
Guizhou Sanli Pharma Elects Vice Chairman	22-12-29	MT
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
GuiZhou SanLi Pharmaceutical Co.,Ltd signed framework agreement to acquire 51% stake in Guizhou Haosite Biotechnology Co., Ltd. from Zhao Guofu.	22-07-27	CI
GuiZhou SanLi Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-21	CI
GuiZhou SanLi Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-21	CI
Guizhou Sanli to Buy Bankrupt Traditional Chinese Medicine Firm Dechangxiang for $37 Million	22-02-07	MT

Chart GuiZhou SanLi Pharmaceutical Co.,Ltd

Duration

Period

Chart GuiZhou SanLi Pharmaceutical Co.,Ltd

More charts

Guizhou Sanli Pharmaceutical Co Ltd is a company mainly engaged in the research and development, production and sales of Chinese patent medicines. The Company's product lines cover various areas, including pediatrics, respiratory systems, cardio-cerebrovascular and gastroenterology. Its main products are Kaihoujian spray (Pediatric Use), Kaihoujian spray and Qiangli Gastrodia Elata Eucommia capsules. The Kaihoujian spray (Pediatric Use) and Kaihoujian spray are used for the treatment of respiratory and oral diseases, and the Qiangli Gastrodia Elata Eucommia capsule is used for the treatment of cardiovascular and cerebrovascular diseases. The Company mainly sells its products through specialized academic marketing.

Sector

Pharmaceuticals

Calendar

2024-05-17 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for GuiZhou SanLi Pharmaceutical Co.,Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.3 CNY

Average target price

19.84 CNY

Spread / Average Target

+21.72%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GUIZHOU SANLI PHARMACEUTICAL CO.,LTD	-13.67%	920M
ELI LILLY AND COMPANY	+29.98%	682B
NOVO NORDISK A/S	+31.87%	586B
JOHNSON & JOHNSON	-3.52%	364B
MERCK & CO., INC.	+18.59%	327B
ABBVIE INC.	+4.07%	285B
ASTRAZENECA PLC	+16.52%	240B
NOVARTIS AG	+9.45%	209B
ROCHE HOLDING AG	-8.83%	203B
AMGEN INC.	+7.09%	165B

Other Pharmaceuticals